Breast cancer

April 15, 2020

Now Enrolling: EA1181 Decreasing Chemotherapy in HER2 Positive Breast Cancer

For patients who have a pathologic complete response (pCR) after 12 weeks of pre-operative THP (single agent taxane plus trastuzumab and pertuzumab), is it safe to omit additional therapy after surgery?
January 14, 2020

From the Co-Chairs, December 2019/January 2020

Reflecting on key milestones in 2019: TMIST breast cancer screening trial continues to ramp up; NCORP grant renewal emphasizes screening, symptom control, and cancer care delivery research; new role for Dr. Al Benson; E1912's practice-changing trial results; update on Dr. Otis Brawley's efforts to form the Social Determinants of Health Working Group; EA launches the Comis Symposium